Maecke HR - Search Results

1

Reply to: Appearances are often deceptive.

Boy C, Lahner H, Maecke HR, Bockisch A, Poeppel TD. Boy C, et al. Among authors: maecke hr. Nuklearmedizin. 2018 Aug;57(4):168-169. doi: 10.1055/s-0038-1668503. Epub 2018 Aug 20. Nuklearmedizin. 2018. PMID: 30125930 No abstract available.

2

[Somatostatin receptor PET/CT (SSTR-PET/CT)].

Boy C, Poeppel T, Kotzerke J, Krause BJ, Amthauer H, Baum RP, Buchmann I, Ezziddin S, Führer D, Gabriel M, Kuwert T, Lahner H, Lauenstein T, Maecke HR, Nagarajah J, Rösch F, Scheidhauer K, Schmidt M, Walter MA, Bockisch A. Boy C, et al. Among authors: maecke hr. Nuklearmedizin. 2018 Feb;57(1):4-17. doi: 10.1055/s-0038-1636560. Epub 2018 Feb 21. Nuklearmedizin. 2018. PMID: 29536494 German.

3

Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?

Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, Maecke H. Antunes P, et al. Eur J Nucl Med Mol Imaging. 2007 Jul;34(7):982-93. doi: 10.1007/s00259-006-0317-x. Epub 2007 Jan 16. Eur J Nucl Med Mol Imaging. 2007. PMID: 17225119 Free article.

4

Reply: Somatostatin Receptor-Targeted Radiopeptide Therapy in Patients with Progressive Unresectable Meningioma.

Radojewski P, Dumont RA, Marincek N, Brunner P, Müller-Brand J, Maecke HR, Briel M, Walter MA. Radojewski P, et al. Among authors: maecke hr. J Nucl Med. 2016 Oct;57(10):1657-1658. doi: 10.2967/jnumed.116.178145. Epub 2016 Jun 30. J Nucl Med. 2016. PMID: 27363835 Free article. No abstract available.

5

Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial.

Marincek N, Radojewski P, Dumont RA, Brunner P, Müller-Brand J, Maecke HR, Briel M, Walter MA. Marincek N, et al. Among authors: maecke hr. J Nucl Med. 2015 Feb;56(2):171-6. doi: 10.2967/jnumed.114.147256. Epub 2015 Jan 15. J Nucl Med. 2015. PMID: 25593116 Free article. Clinical Trial.

6

The prognostic and predictive value of sstr₂-immunohistochemistry and sstr₂-targeted imaging in neuroendocrine tumors.

Brunner P, Jörg AC, Glatz K, Bubendorf L, Radojewski P, Umlauft M, Marincek N, Spanjol PM, Krause T, Dumont RA, Maecke HR, Müller-Brand J, Briel M, Schmitt A, Perren A, Walter MA. Brunner P, et al. Among authors: maecke hr. Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):468-475. doi: 10.1007/s00259-016-3486-2. Epub 2016 Aug 18. Eur J Nucl Med Mol Imaging. 2017. PMID: 27539020 Free article. Clinical Trial.

7

Radiopharmaceuticals for somatostatin receptor imaging.

Mikołajczak R, Maecke HR. Mikołajczak R, et al. Among authors: maecke hr. Nucl Med Rev Cent East Eur. 2016;19(2):126-32. doi: 10.5603/NMR.2016.0024. Nucl Med Rev Cent East Eur. 2016. PMID: 27479790 Free article. Review.

8

Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy.

Ginj M, Chen J, Walter MA, Eltschinger V, Reubi JC, Maecke HR. Ginj M, et al. Among authors: maecke hr. Clin Cancer Res. 2005 Feb 1;11(3):1136-45. Clin Cancer Res. 2005. PMID: 15709181

9

Influence of different spacers on the biological profile of a DOTA-somatostatin analogue.

Antunes P, Ginj M, Walter MA, Chen J, Reubi JC, Maecke HR. Antunes P, et al. Among authors: maecke hr. Bioconjug Chem. 2007 Jan-Feb;18(1):84-92. doi: 10.1021/bc0601673. Bioconjug Chem. 2007. PMID: 17226960

10

Electron- and positron-emitting radiolanthanides for therapy: aspects of dosimetry and production.

Uusijärvi H, Bernhardt P, Rösch F, Maecke HR, Forssell-Aronsson E. Uusijärvi H, et al. Among authors: maecke hr. J Nucl Med. 2006 May;47(5):807-14. J Nucl Med. 2006. PMID: 16644751 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

150 results

Search Page